Home » Stocks » MTNB

Matinas BioPharma Holdings, Inc. (MTNB)

Stock Price: $1.64 USD 0.08 (5.13%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 327.41M
Revenue (ttm) 95,833
Net Income (ttm) -22.49M
Shares Out 198.91M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $1.64
Previous Close $1.56
Change ($) 0.08
Change (%) 5.13%
Day's Open 1.59
Day's Range 1.51 - 1.64
Day's Volume 4,615,340
52-Week Range 0.52 - 1.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 weeks ago

Matinas has an OM3 drug that has demonstrated a superior profile to Amarin's Vascepa. It has a platform and, unlike Amarin, a diverse pipeline.

The Motley Fool - 3 weeks ago

The proposed brand name for its leading pipeline drug got an important nod.

GlobeNewsWire - 1 month ago

BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therape...

GlobeNewsWire - 1 month ago

- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 -

GlobeNewsWire - 1 month ago

– Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules – – Dr. Liu brings more t...

Zacks Investment Research - 1 month ago

Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

GlobeNewsWire - 2 months ago

BEDMINSTER, N.J., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therape...

GlobeNewsWire - 2 months ago

BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therape...

Seeking Alpha - 2 months ago

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

EnACT study of MAT2203 in cryptococcal meningitis received unanimous D ata and Safety Monitoring Board (DSMB) recommendation to pro ceed into second patient cohort

GlobeNewsWire - 3 months ago

BEDMINSTER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a...

GlobeNewsWire - 3 months ago

– DSMB evaluated both safety and efficacy data in recommending cohort progression –

InvestorPlace - 3 months ago

If you're itching for a little excitement in your investing, these cheap stocks under $1 might be just what you're looking for. The post 7 Cheap Stocks Under $1 That Deserve A Second Look appe...

Other stocks mentioned: AMPE, GPL, GPOR, GSM, TRQ, TRX
GlobeNewsWire - 4 months ago

BEDMINSTER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an...

GlobeNewsWire - 4 months ago

Topline data expected first quarter 2021 Topline data expected first quarter 2021

GlobeNewsWire - 4 months ago

BEDMINSTER, N.J., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...

GlobeNewsWire - 5 months ago

Data published in Antimicrobial Agents and Chemotherapy demonstrate MAT2203 (oral amphotericin B) is well tolerated without the side effects commonly seen with IV amphotericin B Data published...

Seeking Alpha - 5 months ago

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020.

Benzinga - 5 months ago

On Monday, August 10, Matinas BioPharma Hldgs (AMEX: MTNB) will release its latest earnings report.

GlobeNewsWire - 5 months ago

BEDMINSTER, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...

Zacks Investment Research - 5 months ago

Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 5 months ago

BEDMINSTER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, ...

Zacks Investment Research - 6 months ago

Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 6 months ago

-   Topline data from ENHANCE-IT study of MAT9001 vs. Vascepa® expected in Q1 2021   - 

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor of Matinas BioPharma

Seeking Alpha - 8 months ago

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahe...

GlobeNewsWire - 9 months ago

BEDMINSTER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United St...

Seeking Alpha - 10 months ago

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended December 2019.

GlobeNewsWire - 10 months ago

Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020

GlobeNewsWire - 10 months ago

– Topline data expected Q4 2020 –

GlobeNewsWire - 10 months ago

President of American Board of Clinical Lipidology and nationally recognized expert in cardiovascular disease prevention and the diagnosis and treatment of cholesterol and hypertensive disorde...

GlobeNewsWire - 11 months ago

– Part 2 efficacy portion of EnACT expected to commence Q1 2020 –

InvestorPlace - 11 months ago

While some argue you get what you pay for, others say that stocks trading at low levels can represent compelling opportunities.

Other stocks mentioned: DRRX, NOG, TAST, VBIV
Zacks Investment Research - 1 year ago

Prospects Appear Bright for Small Drug Industry in 2020

Other stocks mentioned: AMRX, COLL, KALV
GlobeNewsWire - 1 year ago

BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, ...

The Motley Fool - 1 year ago

The company announced the pricing of a public stock offering.

GlobeNewsWire - 1 year ago

BEDMINSTER, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, ...

GlobeNewsWire - 1 year ago

BEDMINSTER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, ...

The Motley Fool - 1 year ago

The small-cap pharma sank on an update from its top competitor.

Seeking Alpha - 1 year ago

Matinas And Amarin, And Other News And Issues: The Good, Bad, And Ugly Of Biopharma

Other stocks mentioned: AMRN
InvestorPlace - 1 year ago

Snapping up strong buy stocks with great long-term growth prospects doesn’t have to cost you your entire savings. The post 5 Strong Buy Stocks Under $5 With Massive Upside Potential appeared ...

Other stocks mentioned: ITI, OGI, OVID, PLUG
The Motley Fool - 1 year ago

Good news for its competitor Amarin has investors nervous about Matinas' cardiovascular disease drug MAT9001.

GlobeNewsWire - 1 year ago

BEDMINSTER, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a ...

GlobeNewsWire - 1 year ago

BEDMINSTER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Ch...

Seeking Alpha - 1 year ago

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2019.

Seeking Alpha - 1 year ago

Liver Therapy Forum weekly digest provides an overview of therapeutics in development for hypertriglyceridemia in 2019. The focus this week is on Matinas BioPharma.

Other stocks mentioned: AMRN

About MTNB

Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The compa... [Read more...]

Industry
Biotechnology
Founded
2013
CEO
Jerome Jabbour
Employees
21
Stock Exchange
NYSEAMERICAN
Ticker Symbol
MTNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for MTNB stock is "Buy." The 12-month stock price forecast is 3.75, which is an increase of 128.66% from the latest price.

Price Target
$3.75
(128.66% upside)
Analyst Consensus: Buy